The 2 most recent market catalysts affecting $SPRY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 75
ARS Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results.
The mixed Q2 financial results for ARS Pharmaceuticals (SPRY) are a direct corporate catalyst, leading to a negative market reaction. Investors are likely weighing the positive asp…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate
ARS Pharmaceuticals (SPRY) announced Q2 earnings that showed a substantial miss on EPS expectations, reporting $(0.63) against an estimated $(0.48). This 31.25% miss, coupled with …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.